AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10584043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (25.3% total fat, 6.1% saturated fat)
Number of subjects: 103
Study 10584043 — intervention group
Group type: EXPERIMENTAL
Intervention: Average American Diet (AAD)
Number of subjects: 103
Study 10584043 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association Step I diet
Number of subjects: 103
Study 10584043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 103
Study 10584043 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced changes in serum triacylglycerol
Number of subjects: 103
Study 9005824 — intervention group
Group type: EXPERIMENTAL
Intervention: Destructive changes in B-cells
Number of subjects: 49
Study 9005824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosis and hyalinosis of vascular wall
Number of subjects: 49
Study 9005824 — intervention group
Group type: EXPERIMENTAL
Intervention: Langerhans islands sclerosis
Number of subjects: 49
Study 9005824 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal structure of the acinar compartment of the pancreas
Number of subjects: 49
Study 2015167 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50
Study 2015167 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 50
Study 6688538 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin, and 5-fluorouracil)
Number of subjects: 0
Study 6688538 — intervention group
Group type: COMPARATOR
Intervention: CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone)
Number of subjects: 0
Study 6688538 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 0
Study 6688538 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin-containing combinations
Number of subjects: 0
Study 31046165 — intervention group
Group type: EXPERIMENTAL
Intervention: Day clinic (DC) management model
Number of subjects: 470
Study 31046165 — intervention group
Group type: COMPARATOR
Intervention: Hospital inpatient care
Number of subjects: 470
Study 28257940 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral treatment (ABT)
Number of subjects: 190
Study 28257940 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 190
Study 25743263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (600-1200 µg bid for at least 6 months)
Number of subjects: 8
Study 23530172 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneously descended testis
Number of subjects: 91
Study 23530172 — intervention group
Group type: COMPARATOR
Intervention: Boys operated on at 3 years
Number of subjects: 91
Study 23530172 — intervention group
Group type: COMPARATOR
Intervention: Boys operated on at 9 months
Number of subjects: 91
Study 21696245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS), a peanut-based micronutrient fortified paste
Number of subjects: 45
Study 21696245 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning strategies (including gradual reduction of breast-feeding, expressing breast-milk into a cup, and separation of mother and child)
Number of subjects: 45
Study 19783896 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin plus 10 mg of ezetimibe
Number of subjects: 98
Study 19783896 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin
Number of subjects: 98
Study 19783896 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin plus 10 mg of ezetimibe (after crossover)
Number of subjects: 98
Study 19783896 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin (initially)
Number of subjects: 98
Study 16432273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (Ginkgold, 3 doses of 120 mg)
Number of subjects: 11
Study 16432273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12543214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 18
Study 12543214 — intervention group
Group type: COMPARATOR
Intervention: Placebo mixture (nutritionally balanced amino acid mixture containing tryptophan)
Number of subjects: 18
Study 11351835 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent pornography use, particularly violent pornography
Number of subjects: 0
Study 11351835 — intervention group
Group type: EXPERIMENTAL
Intervention: Men at high risk for sexual aggression
Number of subjects: 0
Study 9432291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (Lescol, Sandoz Pharma Ltd) 20 mg once daily, increased to 40 mg if LDL‐Ch > 3.5 mmol/l
Number of subjects: 62
Study 9432291 — intervention group
Group type: COMPARATOR
Intervention: Control group on low fat and low cholesterol diet
Number of subjects: 62
Study 1528206 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (equal to daily caffeine consumption)
Number of subjects: 62
Study 1528206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3880874 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7
Study 3880874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31711422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic preconditioning (HPC)
Number of subjects: 70
Study 31711422 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 29777823 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, 1200 mg, intravenously every 3 weeks
Number of subjects: 2075
Study 29777823 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel, 75 mg/m2, intravenously every 3 weeks
Number of subjects: 2075
Study 27105870 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich triglyceride concentrates (3.1 g EPA/d)
Number of subjects: 48
Study 27105870 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich triglyceride concentrates (2.9 g DHA/d)
Number of subjects: 48
Study 27105870 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil (placebo)
Number of subjects: 48
Study 25295645 — intervention group
Group type: EXPERIMENTAL
Intervention: MDX 1400 mg
Number of subjects: 36
Study 25295645 — intervention group
Group type: COMPARATOR
Intervention: MDX 700 mg
Number of subjects: 36
Study 25295645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22537617 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 0.5 mg every 4 weeks (0.5q4)
Number of subjects: 221
Study 22537617 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2 mg every 4 weeks (2q4)
Number of subjects: 221
Study 22537617 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2 mg every 8 weeks after 3 initial monthly doses (2q8)
Number of subjects: 221
Study 22537617 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2 mg as needed after 3 initial monthly doses (2PRN)
Number of subjects: 221
Study 22537617 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 221
Study 22537617 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye groups (combined)
Number of subjects: 221
Study 20168206 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcised men
Number of subjects: 4889
Study 20168206 — intervention group
Group type: COMPARATOR
Intervention: Uncircumcised men
Number of subjects: 4889
Study 20168206 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected insertive anal sex with HIV-positive partner
Number of subjects: 4889
Study 20168206 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected receptive anal sex with HIV-positive partner
Number of subjects: 4889
Study 20168206 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of being uncircumcised and unprotected insertive anal sex
Number of subjects: 4889
Study 20168206 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of being uncircumcised and unprotected receptive anal sex
Number of subjects: 4889
Study 20168206 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision status
Number of subjects: 4889
Study 17698601 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain
Number of subjects: 139
Study 17698601 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety
Number of subjects: 139
Study 16213930 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (12 mg/kg on days 1-5, repeated on days 11-15 and days 21-25)
Number of subjects: 22
Study 16213930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered in the same regimen for a 30-day period)
Number of subjects: 22
Study 12117201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chlorite mouthrinse acidified with malic acid
Number of subjects: 36
Study 12117201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chlorite mouthrinse acidified with gluconic acid
Number of subjects: 36
Study 12117201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 36
Study 12117201 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC rinse
Number of subjects: 36
Study 12117201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chlorite rinse
Number of subjects: 36
Study 12117201 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 36
Study 9658884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 day 1 and etoposide 120 mg/m2 on days 1-3, with vinblastine 5 mg/m2 on days 1 and 3 (in 58 patients)
Number of subjects: 92
Study 9658884 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m2 day 1 and etoposide 120 mg/m2 on days 1-3 (without vinblastine)
Number of subjects: 92
Study 9658884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide treatment
Number of subjects: 92
Study 7846096 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortification (soup fortified with 20 mg iron and 100 mg vitamin C for 15 weeks on school days)
Number of subjects: 30
Study 3229833 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 106
Study 3229833 — intervention group
Group type: COMPARATOR
Intervention: Plaster treatment
Number of subjects: 106
Study 29604402 — intervention group
Group type: COMPARATOR
Intervention: Aquatic exercise
Number of subjects: 40
Study 29604402 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise
Number of subjects: 40
Study 27993963 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs28714259
Number of subjects: 3431
Study 25958946 — intervention group
Group type: EXPERIMENTAL
Intervention: Full squat training (n=36)
Number of subjects: 122
Study 25958946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined full squat and sprint training (n=32)
Number of subjects: 122
Study 25958946 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed training only (n=34)
Number of subjects: 122
Study 25958946 — intervention group
Group type: COMPARATOR
Intervention: Non-training control group (n=20)
Number of subjects: 122
Study 23890742 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel alcohol-based hand rub (ABHR) formulations
Number of subjects: 0
Study 23890742 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid alcohol-based hand rub (ABHR) formulations
Number of subjects: 0
Study 21205043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS) for 12 weeks
Number of subjects: 761
Study 21205043 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 761
Study 18461848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanen Parent Program (experimental treatment group)
Number of subjects: 17
Study 18461848 — intervention group
Group type: COMPARATOR
Intervention: Waiting-control group (matched control group)
Number of subjects: 17
Study 18461848 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent intervention ratings
Number of subjects: 17
Study 16476889 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal residua of retinopathy of prematurity (ROP)
Number of subjects: 247
Study 16476889 — intervention group
Group type: COMPARATOR
Intervention: No retinal residua of retinopathy of prematurity (ROP)
Number of subjects: 247
Study 16476889 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal ablation treatment for severe acute-phase ROP
Number of subjects: 247
Study 14574544 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 32
Study 14574544 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 32
Study 10382135 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with Down syndrome
Number of subjects: 44
Study 10382135 — intervention group
Group type: COMPARATOR
Intervention: Controls without mental retardation
Number of subjects: 44
Study 10382135 — intervention group
Group type: EXPERIMENTAL
Intervention: Life events from the past year
Number of subjects: 44
Study 8882477 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha plus cis‐platinum
Number of subjects: 56
Study 8882477 — intervention group
Group type: COMPARATOR
Intervention: No antitumor therapy
Number of subjects: 56
Study 2071558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 20
Study 2071558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6664741 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-cyanidanol-3 (Catergen) plus prednisolone
Number of subjects: 36
Study 6664741 — intervention group
Group type: COMPARATOR
Intervention: Control (prednisolone only)
Number of subjects: 36
Study 6664741 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-cyanidanol-3 (Catergen)
Number of subjects: 36
Study 28816554 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral abdominal sacral hysteropexy (BASH)
Number of subjects: 30
Study 28816554 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical abdominal sacral hysteropexy (ASH)
Number of subjects: 30
Study 26472511 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoPulse
Number of subjects: 29
Study 26472511 — intervention group
Group type: COMPARATOR
Intervention: LUCAS 2
Number of subjects: 29
Study 25975423 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice daily + Telaprevir 750 mg every 8 hours
Number of subjects: 0
Study 25975423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily + Telaprevir 750 mg every 8 hours
Number of subjects: 0
Study 25975423 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir
Number of subjects: 0
Study 24669604 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 180
Study 24669604 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 180
Study 20945743 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Adper SE Plus, 3M ESPE)
Number of subjects: 56
Study 20945743 — intervention group
Group type: COMPARATOR
Intervention: Etch & rinse adhesive (Adper Single Bond 2, 3M ESPE)
Number of subjects: 56
Study 20945743 — intervention group
Group type: COMPARATOR
Intervention: Thermocycling (500 cycles between 5 degrees C and 55 degrees C)
Number of subjects: 56
Study 18175072 — intervention group
Group type: EXPERIMENTAL
Intervention: Work style intervention (WS and WSPA)
Number of subjects: 466
Study 18175072 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (C)
Number of subjects: 466
Study 16181539 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower Yellow injection (SYI)
Number of subjects: 448
Study 16181539 — intervention group
Group type: COMPARATOR
Intervention: Salvia injection (Control)
Number of subjects: 448
Study 14625518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice treatment with light shoulder exercise (ILSE)
Number of subjects: 7
Study 14625518 — intervention group
Group type: EXPERIMENTAL
Intervention: Light shoulder exercise (LSE)
Number of subjects: 7
Study 14625518 — intervention group
Group type: COMPARATOR
Intervention: Ice treatment (IT)
Number of subjects: 7
Study 14625518 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study 10507602 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium replacement (Se+), sodium selenite for 9 days (535 microg for 3 days, 285 microg for 3 days, and 155 microg for 3 days), then 35 microg per day iv.
Number of subjects: 42
Study 10507602 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium replacement (Se+), sodium selenite for 9 days, then 35 microg per day iv.
Number of subjects: 42
Study 10507602 — intervention group
Group type: COMPARATOR
Intervention: Control group (Se-), received 35 microg of sodium selenite throughout the treatment period.
Number of subjects: 42
Study 10507602 — intervention group
Group type: COMPARATOR
Intervention: Control group (Se-), overall mortality.
Number of subjects: 42
Study 8945145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Number of subjects: 83
Study 8945145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 1662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of DLIS using radioimmunoassay (RIA)
Number of subjects: 163
Study 1662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of DLIS using affinity mediated immunoassay (ACA)
Number of subjects: 163
Study 1662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of DLIS using fluorescence polarization immunoassay (TDX I)
Number of subjects: 163
Study 1662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall detection of DLIS using all 3 assays
Number of subjects: 163
Study 1662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean serum digoxin concentration
Number of subjects: 163
Study 1662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of DLIS in patients with delayed allograft function
Number of subjects: 163
Study 1662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of DLIS in patients without delayed allograft function
Number of subjects: 163
Study 1662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical significance of DLIS persistence
Number of subjects: 163
Study 7158232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol-17 beta orally (2-4 mg)
Number of subjects: 38
Study 7158232 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol-17 beta cutaneously (3 mg)
Number of subjects: 38
Study 6705172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingually)
Number of subjects: 32
Study 6705172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31664479 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 38
Study 31664479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30191421 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks
Number of subjects: 409
Study 30191421 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks
Number of subjects: 409
Study 30191421 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP (combined doses)
Number of subjects: 409
Study 30191421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 26915841 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Steroid Withdrawal (ESW)
Number of subjects: 71
Study 26915841 — intervention group
Group type: COMPARATOR
Intervention: Control (steroid treatment)
Number of subjects: 71
Study 23990451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (80 mg)
Number of subjects: 125
Study 23990451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 22052899 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time computerized decision support ON
Number of subjects: 1407
Study 22052899 — intervention group
Group type: COMPARATOR
Intervention: Real-time computerized decision support OFF
Number of subjects: 1407
Study 21092442 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 152
Study 21092442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 18034343 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 30
Study 18034343 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 30
Study 18034343 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs
Number of subjects: 30
Study 16155825 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound branch chain amino acids injection (Aminic)
Number of subjects: 80
Study 16155825 — intervention group
Group type: COMPARATOR
Intervention: Amino acids (MPR-F)
Number of subjects: 80
Study 12772221 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic group in supine position after 30 min
Number of subjects: 22
Study 12772221 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic group in supine position after 60 min
Number of subjects: 22
Study 12772221 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic group in supine position
Number of subjects: 22
Study 12772221 — intervention group
Group type: COMPARATOR
Intervention: Control group in supine position
Number of subjects: 22
Study 12772221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups in supine position
Number of subjects: 22
Study 10596256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 11
Study 8686825 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with fentanyl
Number of subjects: 96
Study 8686825 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 96
Study 1923207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle
Number of subjects: 55
Study 1923207 — intervention group
Group type: COMPARATOR
Intervention: Novak
Number of subjects: 55
Study 6122056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine alone (7-day in-vivo test and 48 h in-vitro test)
Number of subjects: 24
Study 6122056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (7-day in-vivo test)
Number of subjects: 24
Study 30896757 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus cisplatin
Number of subjects: 788
Study 30896757 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin
Number of subjects: 788
Study 30896757 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Number of subjects: 788